dailyvideo

New breast cancer treatment as a first-line therapy in HER2-positive metastatic disease

Scientists have reported that a new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease. Excited scientists say the new generation of drugs, to be announced at a leading cancer conference this week, could be used effectively against many types of tumor, Daily reports Express.The treatment, that have proven successful in studies of breast cancer patients, combines traditional chemotherapy with yet another new generation of drugs that directly target cancer cells.

Scientists have compared the treatment, code-named T-dm1, a Trojan horse because a killer material is protected by a different chemical and activated only when it hits the enemy-cancer cells. T dm1 is the first of a new type of cancer medicine known as an antibody-drug conjugate. It ties together two existing cancer drugs with the aim of delivering both drugs specifically to cancer cells: trastuzumab, a monoclonal antibody that targets cells that overproduce the protein HER2, and DM11, a chemotherapy agent that targets microtubules.

The technology is developed by the U.S. immunogen in combination with drug giant Roche. We is encouraged by the results, says Edith Perez of the Mayo Clinic.

In trial, Researchers randomly assigned 137 women to treatment with either trastuzumab plus chemotherapy drug docetaxel, or T-DM1. All participants had HER2-positive metastatic cancer, no prior chemotherapy for metastatic disease. After a median of about 6 months of follow-up, The researchers found an overall response rate of 48 pc in patients with T-dm1, compared with 41 pc of trastuzumab plus docetaxel arm.

Importantly, the rates of clinically relevant adverse events was significantly lower in T-dm1 arm (37 pc) compared to the cost in women given traztuzumab plus docetaxel (75 pc). This trial is ongoing and the positive results is to generate enthusiasm for a larger phase III study is now underway. The study showed that T-dm1 has very high anti-tumor activity and much lower toxicity, she added.

Findings to be presented at the European Society of Medical Oncology conference in Milan.

Posted on Sunday, October 10, 2010. Filed under , . You can follow any responses to this entry through the RSS 2.0

0 comments for New breast cancer treatment as a first-line therapy in HER2-positive metastatic disease

Leave comment

Recent Entries

Recent Comments

Photo Gallery